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ABSTRACT 
Background: D-004, a lipid extract of the fruit of the Cuban royal palm 
(Roystonea regia), has been found to reduce prostatic hyperplasia (PI-I) induced 
with testosterone (T), but not PH induced with dihydrotestosterone (DHT), in 
rodents, suggesting the inhibition of prostate 5cz-reductase activity. 
Objectives: The aims of this study were to assess whether D-004 inhibits 
prostate 5~-reductase activity in vitro and to examine the effects of D-004 on 
enzyme kinetics. 
Methods: This experimental study was conducted at the Pharmacology 
Department, Center of Natural Products, National Center for Scientific Research, 
Havana, Cuba. Soluble rat prostate preparations were used as the source of 
5cz-reductase, and (3H)-DHT production was measured to determine prostate 
5c¢-reductase activity. Cell-free rat prostate homogenates were pre-incubated 
with carboxymethyl cellulose 2% alone (control tubes) or D-004 (0.24- 
125 pg/mL) suspended in the vehicle (treated tubes) for 10 minutes prior to 
adding the labeled substrate (3H)-T. Once the reaction was stopped, sterols 
were extracted with chloroform and aliquots were applied on silica gel plates 
developed in benzene-acetone (4:1, v/v). Areas containing DHT were scraped 
and radioactivity was counted. The median inhibitory concentration (IC50) 
was determined by measuring the conversion of T to DHT. The apparent 
Michaelis-Menten constant (Km) and Vma ~ values before and after adding D-004 
were determined in kinetic studies using labeled T (0.5-25 pmol/L). 
Results: Compared with controls, D-004 significantly and dose-dependently 
inhibited the enzymatic reaction at doses of 1.95 to 125.0 pg/mL (all, P < 0.05). 
The IC50 of D-004 required to inhibit 5~-reductase activity was 2.25 pg/mL. 
Enzyme inhibition was noncompetitive, since D-004 lowered the Vma x from 15.3 
to 10.0 nmol DHT/min • mg -1 protein, while the K m (4.54 pmol/L) was almost 
unaffected. 
Conclusions: D-004 dose-dependently and noncompetitively inhibited in 
vitro 5~-reductase activity in soluble fractions of rat prostate. Although the 
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extent of the maximal inhibition was high and the value of IC50 was low, the rele- 
vance of such inhibition requires further study in vivo. (Curt Ther Res Clin Exp. 
2006;67:396--405) Copyright © 2006 Excerpta Medica, Inc. 
Key words: D-004, free fatty acids, prostate hyperplasia, prostate 50c-reductase 
inhibitors. 
INTRODUCTION 
Benign prostatic hyperplasia (BPH), a term that describes the histologic basis of 
a diagnosis of prostate nlargement, is the uncontrolled growth of granular and 
stromal elements of the prostate gland, which may lead to bladder outflow 
obstruction and difficulty urinating. 1 BPH is common in older men, with a fre- 
quency that increases with age. 1-5 
While the etiology of BPH is not completely understood, it is known to in- 
volve hormonal changes that occur with aging. The development and growth 
of the prostate gland depend on androgen stimulation, mainly by dihydro- 
testosterone (DHT). 1-7 The 50c-reductase enzyme, present as 2 isoforms (types 1 
and 2), converts testosterone (T) to its more potent active metabolite DHT. The 
type 2 isoform is more abundant than the type 1 isoform within the prostate. 6 
Accumulation of DHT in the prostate may encourage cell growth and cause 
hyperplasia, supporting the static component of BPH. 7,8 BPH also involves a 
dynamic omponent, which is associated with an increase in smooth muscle 
tone mediated through the 0ccadrenoceptors under sympathetic nnervation i  
the bladder neck, urethra, and prostate. 9 
Thus, prostate 5oc-reductase inhibitors 1°,11 and 0ccadrenoreceptor blockers 12 
are commonly used to treat BPH. While prostate 50c-reductase inhibitors are ef- 
fective in reducing prostate nlargement and complications, l°al occadrenoreceptor 
blockers are effective in relaxing smooth muscle and improving BPH symp- 
toms. 12 Finasteride, the most prescribed o~-reductase inhibitor, competitively 
and specifically inhibits type 2 5oc-reductase, r ducing prostate volume by 20% 
to 30% and obstructive symptom scores, while increasing peak urinary flow 
rate by 25%. 11 
Herbal medicines, mainly the lipidosterolic extracts (LEs) of saw palmetto 
berries (Serenoa repens), are commonly used to treat BPH. 13-15 Many clinical 
studies have supported the effectiveness of saw palmetto berries, even com- 
pared with finasteride and tamsulosin, to treat BPH, 14-18 although recent placebo- 
controlled trials have found that saw palmetto berries did not improve symp- 
toms or objective measures of BPH more than placebo. 19,2° 
Although the mechanisms supporting the efficacy of the LEs of saw palmetto 
berries in BPH are multiple, 14 it has been found to be an effective dual inhibitor 
of 5oc-reductase isozyme activity in the prostate 21-26 that, unlike other 5oc-reductase 
inhibitors, does not interfere with the cellular capacity to secrete prostate- 
specific antigen. 25 Free fatty acids that are major components of saw palmetto 
berry LEs (eg, oleic, lauric, palmitric, myristic, acids) have been found to inhibit 
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prostate 5c¢-reductase activity, with differential effects on the type 1 and 2 iso- 
forms. 26 However, one study found that LEs of saw palmetto berries did not 
inhibit prostate 5c¢-reductase activity. 27 
D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia), 
contains free fatty acids, with oleic, lauric, palmitic, and myristic acids being 
the most abundant components. 28,29 As mentioned previously, some of them (ie, 
oleic, lauric, palmitic, and myristic acids) have been found to inhibit prostate 
5c¢-reductase activity. 26 
Oral treatment with D-004 reduced prostatic hyperplasia (PH) induced with 
T, 28-31 but not PH induced with DHT, 29 in rodents, suggesting an inhibitory effect 
on prostate 5c¢-reductase activity. 
In light of these issues, this study assessed whether D-004 could inhibit in 
vitro 5c¢-reductase activity in soluble rat prostate fractions. We also investi- 
gated the effects of D-004 on enzyme kinetics. 
MATERIALS AND METHODS 
This experimental study was conducted at the Pharmacology Department, 
Center of Natural Products, National Center for Scientific Research, Havana, 
Cuba. Animal handling was conducted in accordance with the Cuban regula- 
tions for the use of laboratory animals and ethical principles for animal manage- 
ment. The study protocol was reviewed and approved by an independent insti- 
tutional review board. 
Animals 
Male Wistar rats (150-200 g) were acquired from the Center for Laboratory 
Animal Production (CENPALAB, Havana, Cuba) and maintained under standard 
laboratory conditions (temperature 25°C _+ 2°C, relative humidity 65% + 5%, and 
12-hour light/darkness cycles) with access to food (rodent chow) and water ad 
libitum. 
Treatment  
D-004 was obtained from the Chemistry Department of the Center of Natural 
Products (Havana, Cuba), where its composition and purity were assessed 
using a validated gas chromatography method. The free fatty acid composition 
of the tested batch was as follows: caprylic acid (C8:0) 0.4%, capric acid (C10:0) 
0.5%, lauric acid (C12:0) 27.0%, myristic acid (C14:0) 8.5%, palmitic acid (C16:0) 
11.1%, palmitoleic acid (C16:1) 0.4%, stearic acid (Cls:0) 2.0%, oleic acid (C18:1) 
28.5%, linoleic acid (C18:2) 9.5%, and linoleic acid (C18:3) 2.0%. 
Preparat ion of  the Soluble Prostate Fraction 
On the day of the assay, the rats were euthanized under ether anesthesia. The 
ventral prostate glands were immediately removed and blotted prior to their use. 
Unless specified otherwise, the following procedures were conducted at 4°C. 
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The soluble rat prostate fraction was prepared as per the method of George 
et al. 32 In brief, rat prostate tissues were placed in crushed ice and were homog- 
enized in 9 volumes of ice-cold buffer containing sucrose 0.25 mol/L, Tris 
hydrochloride (HC1) 50 mmol/L, and magnesium chloride (MgCI2) 50 mmol/L 
using a polytetrafluoroethylene glass tissue homogenizer (Ultra-Turrax T25, 
Janke and Kunkel GmbH, IKA-Labortechnik, Staufen, West Germany). Homoge- 
nates were centrifuged at 800g for 20 minutes at 4°C, and cell-free homogenates 
with a known protein concentration of 7 mg/mL were then obtained. 
Effects of  D-OO4 on 5~-Reductase Activity 
The in vitro effects of D-004 on enzyme activity were investigated by incubat- 
ing different concentrations of the tissue preparation and determining the dose- 
effect relationship. 
Prostate 5~¢-reductase activity was measured using the method of Kitahara 
et al, 33 with slight modifications. In brief, for 10 minutes prior to adding the 
labeled substrate, the homogenates were preincubated with carboxymethyl cel- 
lulose 2% alone (control tubes) or with different concentrations of D-004 sus- 
pended in this vehicle (treated tubes). Thus control and D-004 tubes were all 
prepared in the same manner, with the only difference being the use of vehicle 
alone or D-004 and vehicle together, espectively. Protein was estimated using a 
modification of the Lowry method. 34 
To calculate the median inhibitory concentration (IC50) values required to in- 
hibit prostate 5c~-reductase activity, tubes containing increasing doses of D-004 
(0.24-125 pg/mL) and those with vehicle alone were preincubated with tissue 
preparations in the presence of a 25-mol/L sucrose solution (1 mL) containing 
Tris HCI 50 mmol/L (pH 7.4), nicotinamide adenine dinucleotide phosphate 
0.3 mmol/L, and MgC12 50 mmol/L. 
After 10 minutes, 2 pmol/L of the labeled substrate [ 1,2,6,7-3HIT (Amersham 
Biosciences, Piscataway, New Jersey) 3.52 Bq/mmol •L -1 containing 20 × 104 dpm 
was added, while stirring constantly. The reaction was carried out in triplicate 
at 37°C for 1 hour, and 3 mL of cold chloroform was added to stop the reaction. 
Cold DHT (50 pg) was added to each tube as a carrier and visualization marker. 
Sterols were extracted with chloroform 3 times. Combined extracts were dried 
under nitrogen at 40°C, dissolved again in chloroform (1 mL), and 200-pL aliquots 
were applied to silica gel plates that were developed in benzene-acetone (4:1, v/v). 
After drying the plates, DHT was visualized with a 50% sulfuric acid solution by 
heating the plates, and areas containing DHT were carefully scraped and trans- 
ferred to scintillation vials. Radioactivity was counted using a scintillation 
counter (model RACKBETA 1219, LKB Wallac, Turku, Finland). The 5~-reductase 
activity was expressed as nanomoles of DHT formed/min • mg -1 protein. 
Twenty rats were used to prepare the soluble prostate homogenates. 
Differences between control and D-004 tubes were estimated from triplicate 
experiments ateach dose. The linearity of enzyme activity versus the time and 
protein concentration was established in initial studies (results not shown). 
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The IC50 values were determined graphically from the curve by plotting the per- 
centage of inhibition of enzyme activity versus the different concentrations of 
D-004. Kinetic studies were done under similar conditions, but the activity of 
the enzyme was measured in the presence of various concentrations of labeled 
T (0.5-25 pmoi/L). A Lineweaver-Burk plot was generated and the values of the 
Michaelis-Menten constant (Km) and Vma x were calculated. Experiments were 
performed in triplicate samples. 
Statistical Analysis 
Data are presented as mean (SD). Statistical comparisons of treated and con- 
trol samples were performed using the 2-tailed Mann-Whitney U test. 
Based on the information obtained with LEs of saw palmetto berries, the 
study was designed to detect a 50% inhibition of enzyme activity with D-004 at 
5.0 pg/mL versus control samples, with a power of 80% at an ~¢ level of 0.05. 
Based on this assumption, we estimated a priori that 2 series of triplicate tubes 
for each dose would be sufficient. 
P < 0.05 was considered statistically significant. Statistical analyses were per- 
formed using Statistics for Windows version 4.2 (StatSoft, Inc., Tulsa, Oklahoma). 
RESULTS 
The table and Figure 1 show the effects of D-004 on DHT formation in the incuba- 
tion medium. Compared with controls, D-004 significantly inhibited in a dose- 
dependent manner the enzymatic reaction at doses of 1.95 to 125.0 pg/mL (all, P < 
0.05). The inhibition was almost complete (-95%) at concentrations >15.62 pg/mL. 
The IC50 of D-004 required to inhibit 5cz-reductase activity was 2.25 pg/mL. 
Figure 2 illustrates the effect of D-004 on the kinetics of 5~-reductase activity. 
The apparent K m and Vma ~ of the enzyme activity were 4.54 pmol/L and 15.3 nmol 
DHT/min • mg -1 protein, respectively. In control conditions, the enzyme appeared 
to be saturated at concentrations >8 pmol/L. Preincubation with D-004 lowered 
Vma x from 15.3 to 10.0 nmol DHT/min • mg -1 protein, while K m remained almost 
unaffected, indicating that the inhibition was noncompetitive. 
DISCUSSION 
The steroid 5~-reductase is a key enzyme in converting several 3-keto steroids 
into their respective 50c-reduced derivatives, governing the conversion of T to 
DHT. 6,8 An increase in prostate 5cz-reductase activity can result in excessively high 
DHT concentrations in the prostate, leading to BPH. 3,4,6'8 The inhibition of 5~z- 
reductase activity is a first-line pharmacologic treatment s rategy for BPH. 1-5'l°'ll 
In this study, we found that D-004, a lipid extract of the fruit of R regia, 28-31 
appeared to inhibit 5cz-reductase activity of soluble fractions of rat prostate in 
vitro in a dose-dependent manner. This result is consistent with the fact that 
oral treatment with D-004 prevented PH induced with T, but not with DHT, in 
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Table. Effects of D-004 on dihydrotestosterone (DHT) generation in soluble fractions 
of rat prostate. 
Enzyme Activity, Mean (SD), 
Treatment nmolDHT/min • mg -1 Protein* Inhibition, % 
Control 4.15 (0.352) - 
D-004 dose 
0.24 tJg/mL 0.7 
0.48 pg/mL 1.7 
0.97 IJg/mL 6.0 
1.95 IJg/mL 27.9 
3.90 IJg/mL 73.8 
15.62 tJg/mL 86.5 
62.5 IJg/mL 95.7 
125.0 tJg/mL 95.4 
4.12 (0.21 3) 
4.08 (0.162) 
3.90 (0.095) 
2.99 (0.195) t
1.09 (0.051)t 
0.56 (0.030) t
0.18 (0.011) t
0.19 (0.003) t
*Values are based on 3 replications of each experiment. 
tp < 0.05 versus control (Mann-Whitney U test). 
0.9 • . D-004 2 IJg/mL 
= Control 
0.8 
~, 0.7 -  
0 .6 -  
0.  
a~ 0 .5 -  
i .4 -  
o 0 .3 -  
0.2 
I I I I I 
0 0.5 1.0 1.5 2.0 2.5 
l IT  (pmol/L) 
Figure 1. Dose-related relationship of the in vitro effect of D-004 on prostate 5~- 
reductase activity. DHT = dihydrotestosterone; T = testosterone. 
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(A) Saturation curve (constructed with mean values of a study performed in 
triplicate samples, at various concentrations of testosterone in the absence 
[control] and presence of D-004 added at inhibitory concentrations) and 
(B) Lineweaver-Burk plot for the inhibition of D-004 on prostate 5~-reductase 
activity. The apparent Michaelis-Menten constant was 4.54 lumol/L and Vma x 
values were 15.3 and 10.0 nmol dihydrotestosterone (DHT)/min • mg -1 pro- 
tein for the control and treated sample, respectively. ICs0 = median inhibi- 
tory concentration. 
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rats. 29 The most abundant components of D-004 are free fatty acids (___85%) 
(eg, oleic, lauric, palmitic, myristic acids), all of which have been found to 
inhibit prostate 5c¢-reductase in vitro. 26,35 Hence, our findings are logical. 
In addition, several studies have found saw palmetto berries to inhibit 
prostate 5(z-reductase activity, thereby preventing prostate growth, 14,15 although 
some results have been discrepant. 27Since D-004 and saw palmetto berries con- 
tain similar LEs, 36,37 their effects on PH induced with T in rodents are similar, 
and their botanic origins are comparable, our findings were expected. Also, the 
almost complete inhibition of enzyme activity (-95%) achieved with D-004 and 
the low 1C50 value (2.25 pg/mL) were similar to the inhibition of enzyme activity 
and the IC50 value (5 pg/mL) reported for the LEs of saw palmetto berries. 22,25 
D-004 inhibited 5c¢-reductase in a noncompetitive manner because it de- 
creased the Vma x of the enzyme reaction without changing the K m, which is dif- 
ferent from the action of competitive inhibitors. This suggests that the inhibi- 
tion induced with D-004, as occurs with the LEs of saw palmetto berries, 22 does 
not involve the binding of the active component(s) of the extract o the site of 
enzyme activity. 
CONCLUSIONS 
The results of this study suggest that D-004 dose-dependently and noncompeta- 
tively inhibits in vitro 5~-reductase activity in soluble fractions of rat prostate 
through a noncompetitive mechanism. Although the maximal inhibition (95%) 
and the low IC50 (2.25 pg/mL) suggest that it could be relevant, he fact that this 
study investigated only the inhibition of D-004 on 5c¢-reductase activity in vitro 
limits its applicability. Therefore, in vivo studies are needed to determine 
whether the inhibitory effects of D-004 are biologically meaningful. 
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